News
MRNS
1.390
-3.47%
-0.050
Weekly Report: what happened at MRNS last week (0415-0419)?
Weekly Report · 3d ago
TANG CAPITAL PARTNERS LP REPORTS 8.2% PASSIVE STAKE IN MARINUS PHARMACEUTICALS INC AS OF APRIL 16 - SEC FILING
Reuters · 6d ago
Analysts’ Top Healthcare Picks: Inspire Medical Systems (INSP), Eli Lilly & Co (LLY)
TipRanks · 04/18 11:30
Marinus Pharmaceuticals Price Target Cut to $10.00/Share From $25.00 by Truist Securities
Dow Jones · 04/18 11:24
Marinus Pharmaceuticals Is Maintained at Buy by Truist Securities
Dow Jones · 04/18 11:24
MARINUS PHARMACEUTICALS INC <MRNS.O>: TRUIST SECURITIES CUTS TARGET PRICE TO $10 FROM $25
Reuters · 04/18 10:55
Maintaining Buy Rating on Marinus: A Balanced View on Future Prospects Despite RSE Setback
TipRanks · 04/18 04:26
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Price target for Amgen Inc. Slashed from $370 to $360. Morgan Stanley raised the price target for Antero Resources Corporation. Urban Outfitters, Inc. Shares fell 0.5% to close at $38.02 on Tuesday. The price target was cut for Unity Biotechnology, Inc.'s shares.
Benzinga · 04/17 12:21
RBC Capital Downgrades Marinus Pharma to Sector Perform, Lowers Price Target to $3
Benzinga · 04/17 09:39
Marinus Pharmaceuticals Cut to Neutral From Outperform by Baird
Dow Jones · 04/17 09:24
Marinus Pharmaceuticals Price Target Cut to $2.00/Share From $20.00 by Baird
Dow Jones · 04/17 09:24
Analysts Question Commercial Viability of Marinus' IV Ganaxolone After Interim Analysis Miss
Marinus Pharmaceuticals Inc’s phase 3 RAISE trial for intravenous ganaxolone failed to meet pre-defined “stopping criteria” The company says the future development of the drug will be assessed. Cantor Fitzgerald says the company has shifted focus to oral ganAXolone.
Benzinga · 04/16 18:45
The Latest Analyst Ratings For Marinus Pharma
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus Pharma has an average price target of $20.71 for the next 12 months. 7 analysts have provided ratings for the company in the past three months. The 12-month price targets offer a snapshot of analysts' perceptions of the company.
Benzinga · 04/16 17:00
Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study
NASDAQ · 04/16 15:46
Marinus Pharmaceuticals Price Target Maintained With a $27.00/Share by HC Wainwright & Co.
Dow Jones · 04/16 15:09
HC Wainwright & Co. Reiterates Buy on Marinus Pharma, Maintains $27 Price Target
Benzinga · 04/16 14:59
Palisade Bio, Marinus Pharmaceuticals, Poseida Therapeutics among healthcare movers
Healthcare On the Move: Palisade Bio, Marinus Pharmaceuticals, Poseida Therapeutics among healthcare movers. S&P 500 Health Care Sector +0.08% to 1617.11. Health Care Equipment & Services among healthcare mover.
Seeking Alpha · 04/16 14:00
Oppenheimer Sticks to Its Hold Rating for Marinus (MRNS)
TipRanks · 04/16 11:35
Maintaining Hold on Marinus Amid Clinical Setbacks and Uncertain Financial Outlook
TipRanks · 04/16 08:46
More
Webull provides a variety of real-time MRNS stock news. You can receive the latest news about Marinus Pharmace through multiple platforms. This information may help you make smarter investment decisions.
About MRNS
Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. The Company is also developing ganaxolone for the treatment of other rare genetic epilepsies, including Tuberous Sclerosis Complex (TSC) and for the treatment of Refractory Status Epilepticus (RSE). It is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.